Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Glucotrack (GCTK) Common Equity (2016 - 2020)

Glucotrack's Common Equity history spans 7 years, with the latest figure at $9.9 million for Q3 2020.

  • For the quarter ending Q3 2020, Common Equity rose 1252.74% year-over-year to $9.9 million, compared with a TTM value of $9.9 million through Sep 2020, up 1252.74%, and an annual FY2019 reading of -$1.4 million, up 50.85% over the prior year.
  • Common Equity for Q3 2020 was $9.9 million at Glucotrack, down from $10.4 million in the prior quarter.
  • The five-year high for Common Equity was $10.9 million in Q1 2020, with the low at -$17.0 million in Q2 2018.
  • Average Common Equity over 5 years is -$6.1 million, with a median of -$9.9 million recorded in 2016.
  • Year-over-year, Common Equity crashed 75.82% in 2016 and then surged 67791.34% in 2020.
  • Tracing GCTK's Common Equity over 5 years: stood at -$10.9 million in 2016, then tumbled by 51.38% to -$16.6 million in 2017, then surged by 82.67% to -$2.9 million in 2018, then surged by 50.85% to -$1.4 million in 2019, then soared by 804.39% to $9.9 million in 2020.
  • Per Business Quant, the three most recent readings for GCTK's Common Equity are $9.9 million (Q3 2020), $10.4 million (Q2 2020), and $10.9 million (Q1 2020).